Multicenter, Observational, Descriptive Study of the Diagnosis, Course and Treatment of Patients With SLE in Routine Practice in Kazakhstan: a Registry Study With Retrospective and Prospective Components.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-15

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multicenter, observational, descriptive study of the diagnosis, course and treatment of patients with SLE in routine practice in Kazakhstan: a registry study with retrospective and prospective components.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in Russia

NCT06759519

Systemic Lupus Erythematosus

COMPLETED

This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLE

NCT06698900

Systemic Lupus Erythematosus

COMPLETED

miR-101-3p and Autotaxin in SLE Patients

NCT07252141

Systemic Lupus Erythematosus (SLE)

NOT_YET_RECRUITING

Safety of Administering Isoniazid to SLE Patients to Prevent TB

NCT06618573

Tuberculosis Systemic Lupus Erythematosus

RECRUITING PHASE2/PHASE3

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

NCT06673043

Lupus Erythematosus, Systemic

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Endpoints

1. Proportion of patients with varying SLE activity assessed by the SLEDAI 2K Activity Index at visits 0, 1, and 2
2. Proportion of patients with PGA changes in dynamics
3. Proportion of patients with changes in dynamics in general clinical tests from baseline data (Visit 0) at visits 1 and 2
4. Proportion of patients with varying SLE organ damage assessed by SLICC/ACR Damage Index - SLICC/ACR DI - SDI at visits 0, 1, and 2;
5. Proportion of patients with prescribed average daily dose of oral corticosteroids at visits 0, 1 and 2

* Prednisone (and equivalents) = 0 mg/day
* Patients with corticosteroids \>0, but less than 5 mg/day; mean daily dose of oral corticosteroids
* Patients with corticosteroids \>5 mg/day: mean daily dose of oral corticosteroids
6. Proportion of patients treated with each line of treatment \[13\] at visits 0, 1, and 2

* Glucocorticoids;
* Cytostatics;
* NSAIDs;
* Biological drugs;
* Immunoglobulins;
* Other significant drugs that affect the course of treatment.

Secondary Endpoints :

1\. Proportion of each sex among patients with SLE 2. Proportion of patients in different age groups 3. Proportion of patients of different races 4. Proportion of patients belonging to different nationalities 5. Proportion of patients with different social status groups 6. Proportion of patients in different BMI classes \[9\] 7. Proportion of patients with different ages of SLE onset and disease duration at diagnosis

* SLE course (relapsing-remitting, chronically active course; SLE remission)
* SLE disease activity (high, moderate, low)
* Average number of SLE exacerbations in the past year;
* Number and reasons for SLE-related hospitalizations and emergency department visits \[11\]
* Number and reasons for non-SLE-related hospitalizations;
* Number and percentage of patients with affected organs (kidneys, lungs, heart, nervous system, hematopoietic system, skin \[10\])
* Changes in the Revised Cutaneous Lupus Erythematosus Disease Areas and Severity Index (R-CLASI) scores 8 Dynamics of treatment results in patients with SLE:
* proportion of patients who achieved remission;
* proportion of patients with a decrease in the degree of SLE activity;
* proportion of patients who achieved low disease activity;
* proportion of patients with various reasons for stopping therapy
* proportion of patients switching drugs 9. Changes in quality of life indicators based on quality of life questionnaires and the presence of fatigue: Questionnaire (LupusQoL) for SLE at visits 0, 1 and 2.

10\. Proportion of patients achieving the combined endpoint LLDAS7.5 at baseline, visits 0, 1, and 2 (LLDAS with prednisone equivalent needed for response ≤ 7.5 mg/day) 11. Proportion of patients achieving the combined endpoint LLDAS5 at baseline, visits 0, 1, and 2 (LLDAS with prednisone equivalent needed for response ≤ 5 mg/day) 12. Proportion of patients achieving clinical remission at baseline, visits 0, 1, and 2.

13\. Changes in symptoms and clinical manifestations in patients with SLE 14. Changes in complications in patients with SLE 15. Proportion of patients with lupus nephritis 16. Changes in non-specific laboratory parameters (at visits 1 and 2 from the initial (visit 0)):
* Complete blood count (CBC);
* Complete urine count (CUA);
* Coagulogram;
* biochemical blood test: creatinine, total protein, ALT, AST, total bilirubin, total cholesterol, glucose;
* CRP
* GFR 17. Changes in immunological criteria:
* Indicators of C3, C4 components of the complement system at visits 0.1 and 2;
* IgG antibodies to double-stranded (native) DNA at visits 0, 1 and 2
* Antinuclear factor on the HEp-2 cell line (ANF) at visits 0 and 2 18. The proportion of patients adherent to treatment based on the Morisky-Green Questionnaire 19. The proportion of patients who had hospitalization and/or an emergency department visit \[11\] 20. The percentage of various reasons for SLE and non-SLE hospitalizations

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Description of SLE Activity in Patients in Routine Practice in the Republic of Kazakhstan Description of the Course of SLE in Patients in the Republic of Kazakhstan Description of Methods and Approaches to the Treatment of Patients With SLE in the Republic of Kazakhstan

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged 18 years and older with a verified diagnosis of SLE
* Patient signed and dated written informed consent form (ICF) by ICH GCP and local legislation prior to inclusion in the study for the prospective observational group.

Exclusion Criteria

* Absence of a signed consent form (ICF) in patients
* Cognitive impairments that hinder understanding the study objectives and completing questionnaires
* Participation in any randomized controlled clinical trial within 3 months prior to inclusion or during participation in this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No